Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

被引：0

作者：

Xiangnan Guan

Ruozhen Hu

Yoonha Choi

Shyam Srivats

Barzin Y. Nabet

John Silva

Lisa McGinnis

Robert Hendricks

Katherine Nutsch

Karl L. Banta

Ellen Duong

Alexis Dunkle

Patrick S. Chang

Chia-Jung Han

Stephanie Mittman

Nandini Molden

Pallavi Daggumati

Wendy Connolly

Melissa Johnson

Delvys Rodriguez Abreu

Byoung Chul Cho

Antoine Italiano

Ignacio Gil-Bazo

Enriqueta Felip

Ira Mellman

Sanjeev Mariathasan

David S. Shames

Raymond Meng

Eugene Y. Chiang

Robert J. Johnston

Namrata S. Patil

机构：

[1] Genentech Inc.,Yonsei Cancer Centre

[2] Sarah Cannon Research Institute/Tennessee Oncology,Faculty of Medicine

[3] PLLC,Clínica Universidad de Navarra

[4] Hospital Universitario Insular de Gran Canaria,undefined

[5] Yonsei University College of Medicine,undefined

[6] Institut Bergonie CLCC Bordeaux,undefined

[7] University of Bordeaux,undefined

[8] CIMA Universidad de Navarra Pamplona,undefined

[9] Vall d’Hebron Institute of Oncology (VHIO),undefined

来源：

Nature | 2024年 / 627卷 / 8005期

关键词：

D O I：

10.1038/s41586-024-07280-9

中图分类号：

学科分类号：

摘要：

引用

页码：E11 / E11

共 50 条

[41] Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Fei Tang
Pan Zheng
Cell & Bioscience, 8
[42] Dendritic cells dictate the responsiveness of PD-L1 blockade in cancer
Mayoux, Maud
Fransen, Marieke F.
Roller, Andreas
Matos, Ines
Pulko, Vesna
Karanikas, Vaios
Umana, Pablo
Klein, Christian
Ossendorp, Ferry A.
Xu, Wei
CANCER RESEARCH, 2017, 77
[43] Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, Joy
Hodgins, Jonathan J.
Marathe, Malvika
Nicolai, Chris J.
Bourgeois-Daigneault, Marie-Claude
Trevino, Troy N.
Azimi, Camillia S.
Scheer, Amit K.
Randolph, Haley E.
Thompson, Thornton W.
Zhang, Lily
Iannello, Alexandre
Mathur, Nikhita
Jardine, Karen E.
Kirn, Georgia A.
Bell, John C.
McBurney, Michael W.
Raulet, David H.
Ardolino, Michele
JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (10): : 4654 - 4668
[44] Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Tang, Fei
Zheng, Pan
CELL AND BIOSCIENCE, 2018, 8
[45] Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Li, Enliang
Huang, Xing
Zhang, Gang
Liang, Tingbo
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
[46] Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors
Salvia, Roser
Rico, Laura G.
Moran, Teresa
Bradford, Jolene A.
Ward, Michael D.
Drozdowskyj, Ana
Climent-Marti, Joan
Martinez-Caceres, Eva M.
Rosell, Rafael
Petriz, Jordi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
[47] Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Enliang Li
Xing Huang
Gang Zhang
Tingbo Liang
Journal of Experimental & Clinical Cancer Research, 40
[48] Dual blockade with α-PD-L1 and α-TIGIT antibodies restores immune activation on dendritic cells and T-cells during LCMV chronic infection
Lazaro-Diezi, Maria
Marini, Miguel A.
Casella, Valentina
Rosa, Laia Bernad
Pique, Eudald Vehi
Pena, Ruth
Rodriguez-Lozano, Gabriel Felipe
Martin-Gayo, Enrique
Meyerhans, Andreas
Prado, Julia G.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1685 - 1685
[49] Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
Tu, Jingyao
Xu, Haoran
Ma, Li
Li, Chunya
Qin, Wan
Chen, Xinyi
Yi, Ming
Sun, Li
Liu, Bo
Yuan, Xianglin
THERANOSTICS, 2022, 12 (02): : 747 - 766
[50] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Hyun Tae Lee
Ju Yeon Lee
Heejin Lim
Sang Hyung Lee
Yu Jeong Moon
Hyo Jeong Pyo
Seong Eon Ryu
Woori Shin
Yong-Seok Heo
Scientific Reports, 7

← 1 2 3 4 5 →